Home › Trials › NCT06219746
Clinical trial Recruiting at 1 site Interventional Ages 18 and up Men only

Using 99mTc-MIP-1404 SPECT/CT for staging prostate cancer

Official title: 99mTc-MIP-1404 SPECT/CT for Primary PROstate Cancer STAging: Comparative Prospective, Randomized Trial to Present Guideline Imaging

Run by Turku University Hospital · NCT06219746 · Data updated 2026-11-12

This study is testing a new imaging technique using a special substance to see if it can give better information about the spread of prostate cancer in high-risk patients compared to standard methods.

Quick facts

Study typeInterventional
Ages18 Years and up
SexMen only
Enrollment320 (estimated)
SponsorTurku University Hospital
Government
Locations1 site (Turku, Southwest Finland)
StatusRecruiting
StartedJune 1, 2022
Main results expectedDecember 31, 2024
Study endsDecember 31, 2026
Registry record updatedJanuary 23, 2024
Trial IDNCT06219746 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are male patients aged 18 years or older with histopathologically confirmed high-risk prostate cancer.

Probably not a fit

Patients with a history of drug or alcohol use that may interfere with study adherence or those who have undergone androgen deprivation therapy prior to enrollment may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the effectiveness of 99mTc-MIP-1404 SPECT/CT imaging in the primary staging of prostate cancer, particularly in high-risk patients. The approach involves administering a single intravenous bolus of 99mTc-MIP-1404, which binds to the PSMA molecule, allowing for enhanced imaging of potential metastases. The goal is to improve the accuracy of staging compared to traditional methods like bone scintigraphy and contrast-enhanced CT scans, which have lower sensitivity for detecting metastasis. By providing more reliable staging information, this study aims to inform treatment decisions for patients diagnosed with prostate cancer.

Why it matters

Potential benefit: If successful, this could lead to more accurate staging of prostate cancer, improving treatment decisions and potentially outcomes for patients.

How similar studies have gone: While the use of PSMA imaging is gaining traction, this specific application of 99mTc-MIP-1404 SPECT/CT in primary staging is relatively novel and has not been extensively tested in prior studies.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Subjects must be able and willing to give written informed consent and to comply with the requirements of this study protocol
* Subjects must be male, aged 18 years or above at Baseline
* Histopathologically confirmed high risk (Gleason ≥4+4, PSA ≥20 and/ or cT≥3a) acinar or ductal adenocarcinoma of prostate

Exclusion Criteria:

* Allergy/sensitivity to study medications or their ingredients
* Subjects unable to provide written informed consent
* Subjects who have any other significant disease or disorder which, in the opinion of the investigator, may either put the subject at risk by participation in the study, or may influence the result of the study.
* Subjects who have a history of drug or alcohol use that, in the opinion of the investigator, would interfere with adherence to study requirements.
* Subjects who have androgen deprivation therapy initiated before enrolment
* Subjects who have claustrophobia

Where it's running

  • University Hospital of Turku, Hospital Distric of Southwest Finland
    Turku, Southwest Finland, Finland     Recruiting

Study contacts

  • Principal investigator: Otto O Ettala — Turku University Hospital

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464Turku University Hospital 33
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.